Ibrutinib: From molecule to medicine

Basit Öğe Kaydı
dc.authorid0000-0001-5673-8408en_US
dc.authorid0000-0002-1039-7756en_US
dc.authorid0000-0001-8028-9462en_US
dc.contributor.authorAyyıldız, Orhan
dc.contributor.authorDemirkan, Fatih
dc.contributor.authorGöker, Hakan
dc.contributor.authorHaznedaroğlu, İbrahim C.
dc.contributor.authorİlhan, Osman
dc.contributor.authorKaynar, Leyla G.
dc.contributor.authorÖzdemir, Evren
dc.date.accessioned2024-04-04T06:51:38Z
dc.date.available2024-04-04T06:51:38Z
dc.date.issued2014en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.description.abstractBruton’s tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is a novel targeted-therapeutic agent modulating BCR, which serves as a covalent irreversible inhibitor of BTK. Ibrutinib significantly alters the composition of the tumor microenvironment in CLL, affecting soluble as well as cellular molecular elements without myelosupression. Ibrutinib is clinically developed as an orally administered anti-cancer agent with lead indications in relapse/refractory and in treatment-naïve patients with B-cell malignancies as a single agent. The clinical activities of Ibrutinib as a drug were shown in the B-cell malignancies, especially in patients with CLL, mantle cell lymphoma (MCL), and Waldenstrom’s macroglobulinemia (WM). Ibrutinib has generated the most extensive results so far in patients with CLL, predominately refractory or relapsed CLL where durable disease control as well as improved progression-free survival (PFS) and overall survival (OS) has been observed. The aim of this review is to outline the pharmacophysiological basis of Ibrutinib treatment as well as the current clinical experience based on the trials. The treatment algorithms of B-lymphoproliferative diseases will continue to be revised to a more personalized approach to treat with improved efficacy devoid of unnecessary toxicity.en_US
dc.identifier.citationAyyıldız, O., Demirkan, F., Göker, H., Haznedaroğlu, İ. C., İlhan, O., Kaynar, L. G. ve diğerleri. (2014). Ibrutinib: From molecule to medicine. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 24(3), 4-14.en_US
dc.identifier.doi10.4999/uhod.14601en_US
dc.identifier.endpage14en_US
dc.identifier.issn1306-133X
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85172173638en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage4en_US
dc.identifier.trdizinidhttps://search.trdizin.gov.tr/yayin/detay/197610en_US
dc.identifier.urihttps://www.uhod.org/pdf/PDF_635.pdf
dc.identifier.urihttps://hdl.handle.net/11468/13828
dc.identifier.volume24en_US
dc.identifier.wosWOS:000342544800002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorAyyıldız, Orhan
dc.language.isoenen_US
dc.publisherUHOD - Uluslararasi Hematoloji Onkoloji Dergisien_US
dc.relation.ispartofUHOD - Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBCRen_US
dc.subjectBTKen_US
dc.subjectCLLen_US
dc.subjectIbrutiniben_US
dc.titleIbrutinib: From molecule to medicineen_US
dc.title.alternativeİbrutinib: Molekülden ilacaen_US
dc.typeOtheren_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Ibrutinib From Molecule to Medicine.pdf
Boyut:
3.52 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu